



- [68] Ismail-Beigi F, Craven T, Banerji MA, *et al.* Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial[J]. *Lancet*, 2010, 376(9739):419-430.
- [69] Ziegler D, Hanefeld M, Ruhnau KJ, *et al.* Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study)[J]. *Diabetologia*, 1995, 38(12):1425-1433.
- [70] Papanas N, Ziegler D. Efficacy of α -lipoic acid in diabetic neuropathy[J]. *Expert Opin Pharmacother*, 2014, 15(18):2721-2731.
- [71] Ziegler D, Hanefeld M, Ruhnau KJ, *et al.* Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy[J]. *Diabetes Care*, 1999, 22(8):1296-1301.
- [72] Ziegler D, Low PA, Litchy WJ, *et al.* Efficacy and safety of antioxidant treatment with α -lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial[J]. *Diabetes Care*, 2011, 34(9):2054-2060.
- [73] Goto Y, Hotta N, Shigeta Y, *et al.* A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy[J]. *Diabet Med*, 1993, 10 Suppl 2:39s-43s.
- [74] Goto Y, Hotta N, Shigeta Y, *et al.* Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study[J]. *Biomed Pharmacother*, 1995, 49(6):269-277.
- [75] Hotta N, Sakamoto N, Shigeta Y, *et al.* Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan[J]. *J Diabetes Complications*, 1996, 10(3):168-172.
- [76] Hotta N, Akanuma Y, Kawamori R, *et al.* Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial[J]. *Diabetes Care*, 2006, 29(7):1538-1544.
- [77] Xiao H, Ma K, Huang D, *et al.* Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain[J]. *World J Clin Cases*, 2021, 9(9):2100-2109.
- [78] 王靖清, 刘艳, 于世家. 芪丹通络颗粒对糖尿病周围神经病变患者神经传导速度及 MDA、SOD、TAOC 的影响 [J]. *中国生化药物杂志*, 2016, 36(3):93-95.
- [79] 杨军华. 芪丹通络颗粒改善糖尿病周围神经病变中医证候及对神经传导速度的影响研究 [J]. *中医临床研究*, 2016, 8(33):71-72.
- [80] 赵海彬, 贾玉玲, 李继峰, 等. 芪丹通络颗粒治疗糖尿病痛性神经病变的疗效及对患者生活质量的影响 [J]. *临床合理用药杂志*, 2019, 12(14):62-63.

• 消 息 •

2025 年 10 月 20 日 “世界镇痛日” ——关注中低收入地区的疼痛管理、研究与教育

自 2004 年国际疼痛学会 (The International Association for the Study of Pain, IASP) 倡议设立 “世界镇痛日”以来, 确定每年 10 月第三个周一为 “世界镇痛日 (Global Day Against Pain)”。每年 10 月第三个周一一起始的一周为 “中国镇痛周”, 期间各地疼痛科可结合实际需求, 举行义诊及宣传活动, 进行疼痛科普教育、疼痛医学知识宣讲等。我们的口号是: “免除疼痛是患者的基本权利, 是医师的神圣职责”。健康所系, 性命相托, 需要我们共同努力, 以敬畏之心做好疼痛医学研究和医疗服务!

2025 年 10 月 20 日 世界镇痛日

2025 年 10 月 20 日~26 日 中国镇痛周

2025 年 1 月~2025 年 12 月 世界抗痛年

2025 世界镇痛日主题: 关注中低收入地区的疼痛管理、研究与教育 (Pain Management, Research, and Education in Low- and Middle-Income Settings)